News & Events about Gilead Sciences Inc.
Gilead Sciences (NASDAQ:GILD Get Rating) had its target price raised by Piper Sandler from $104.00 to $111.00 in a research report sent to investors on Thursday morning, The Fly reports. Piper Sandler currently has an overweight rating on the biopharmaceutical companys stock. A number of other ...
Latest Ratings for GILD
DateFirmActionFromTo Mar 2022BarclaysMaintainsUnderweight Mar 2022RBC CapitalMaintainsOutperform Feb 2022BMO CapitalDowngradesOutperformMarket Perform
View More Analyst Ratings for GILD
View the Latest Analyst Ratings
read more...
NORTHAMPTON, MA / ACCESSWIRE / January 19, 2023 / Dr. Hila Elinav burst into tears of joy when the Israeli Ministry of Health announced a sweeping new HIV screening policy for pregnant women in September.'It was a long-awaited, emotional moment,' says Hila, a member of the Israeli...
Stock Options Channel
12days ago
Investors in Gilead Sciences Inc (GILD) saw new options begin trading today, for the April 21st expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 93 days until expiration the newly trading contracts represent a possible ...
NORTHAMPTON, MA / ACCESSWIRE / January 12, 2023 / Gilead Sciences Every time a serious new COVID-19 virus variant emerges, Gilead virologists Charlotte Hedskog and John Bilello, alongside their teams, mobilize as so-called 'variant hunters.'Their mission is to determine whether...